Key Takeaways
- InterVenn Biosciences appoints Alec Ford and Mitch Levine to its Board of Directors as part of its commercialization strategy for glycoproteomic diagnostics.
- Ford has over 30 years in genomics and biotechnology, previously holding leadership roles at Myriad Genetics and Novartis.
- Levine has extensive experience in finance and corporate strategy, having led various successful biotech ventures, including Prenostics and Oncocyte.
New Board Members Join InterVenn Biosciences
InterVenn Biosciences has announced the appointment of Alec Ford and Mitch Levine to its Board of Directors amid its efforts to commercialize glycoproteomic diagnostic solutions. This strategic addition comes as the company aims to integrate glycoproteomics into clinical practice, enabling better clinical decision-making for complex diseases. InterVenn’s diagnostic solutions intend to reveal biological signals often overlooked by traditional genomics and proteomics.
Alec Ford brings over 30 years of experience in the genomics, pharmaceutical, and biotechnology sectors. Currently serving as the CEO of Karius, he has a notable history that includes the role of Chief Operating Officer at Myriad Genetics, where he successfully launched and scaled various business units focused on women’s health, oncology, urology, and prenatal care. Ford’s leadership experience extends to significant roles at renowned companies like Novartis, Sanofi, Nektar Therapeutics, and Pfizer. He is also a founding board member of BioUtah.
Mitch Levine adds a wealth of expertise in finance and corporate strategy within the biotechnology and diagnostics space. He is the current CEO of Prenostics and previously held positions as CEO and board chair at SmartHealth Diagnostics, overseeing advancements in digital imaging and laboratory expansion. Levine’s background includes serving as Chief Financial Officer at Oncocyte, where he managed multiple capital raises and strategic acquisitions. He is involved as an independent director at Codetta BioSciences and chairs the board at Clarus Dx, in addition to having previously chaired the board at ImmunoPrecise Antibodies. Levine founded Enable Capital Management in 2000, aiming to provide growth capital to companies in technology and life sciences.
InterVenn expresses confidence that the combined skillset of Ford and Levine in diagnostics commercialization, operational scaling, and financial strategy will propel the company’s development and growth in precision medicine. Andrew Quong, Ph.D., the CEO of InterVenn, stated, “We are excited to welcome Alec and Mitch to InterVenn’s Board of Directors at a pivotal moment for the company. Their combined expertise will help accelerate our mission to bring glycoproteomics into clinical practice and unlock a new frontier in precision medicine.”
The content above is a summary. For more details, see the source article.